Minerva Neurosciences (NERV) Stock Price

Minerva Neurosciences Price

NASDAQ·CLOSED
3.19
​
Market closed

For Minerva Neurosciences, the net margin of 4.7% is up versus -175.3% a few years ago. The consensus 12-month price target for Minerva Neurosciences is 10.00 USD, about 213.5% above where the stock trades today. Of 9 analysts, 7 rate the stock a buy — an overall Buy consensus.

Minerva Neurosciences stock price

Access this data via the Eulerpool API

Minerva Neurosciences business model & stock analysis

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The company went IPO on 2014-06-25. The firm is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The firm's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

Frequently asked questions about Minerva Neurosciences

Analysts currently set an average price target of 10.00 USD for the Minerva Neurosciences stock (median: 10.00 USD), implying +213.5 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the Minerva Neurosciences stock: 7 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Minerva Neurosciences to generate revenue of 19.76 M USD and earnings per share of -9.81 USD.

Converted at the current exchange rate, the Minerva Neurosciences share trades at 2.85 EUR (3.19 USD).

The Minerva Neurosciences share (NERV) is listed on 1 stock exchanges, including: NASDAQ (NERV).

The expected revenue of Minerva Neurosciences is 19.76 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Minerva Neurosciences is -109.04 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Minerva Neurosciences is currently -0.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Minerva Neurosciences stock.

The price-to-sales ratio (P/S) of Minerva Neurosciences is currently 1.80. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Minerva Neurosciences stock.

The Eulerpool Quality Score for Minerva Neurosciences is 1/10.

The ISIN of Minerva Neurosciences is US6033802058. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Minerva Neurosciences is A1171S. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Minerva Neurosciences is NERV. The ticker symbol is used to trade Minerva Neurosciences shares on the stock exchange.

Fair ValueTerminal
2.97 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jun 25, 2014
ISIN
US6033802058
Cusip
603380106
Sedol
BNB7PK5
Market capitalization
138.03 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.33
P/Ee 2027
-1.21
P/Ee 2028
-1.67
P/Ee 2029
-1.95
P/Ee 2030
4.12
P/S
P/Se
1.80
EV/EBIT
—
P/B Ratio
17.31
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
208.47 %
Last updated Oct 11, 2026, 9:58 PM

Minerva Neurosciences Ticker

NASDAQ · NERV